drugset / Trial / NCT07125222
Use of Gocovri to Improve Disability Due to Radiation Encephalopathy
Phase 2
Not yet recruiting
24 enrolled
Weill Medical College of Cornell University
Supernus Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
A study to assess the effect of Gocovri (extended-release amantidine) to improve disability as assessed by the disability rating scale (DRS) and cognition as assessed by the Montreal Cognitive Assessment (MoCA) test in patients with radiation encephalopathy.
Timeline
- Start
- 2025-09
- Primary completion
- 2028-08
- Completion
- 2028-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amantadine | Unknown | 274 mg | — |
Indications
No indication recorded.